Discover trends, market shifts, and competitive outlooks for the neurotrophic keratitis treatment industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What is the Anticipated CAGR of the Neurotrophic Keratitis Treatment Market, and What Factors Will Drive It?
The market for treating neurotrophic keratitis has seen robust growth lately. Its size is projected to increase from $5.1 billion in 2024 to $5.51 billion in 2025, indicating a compound annual growth rate (CAGR) of 8.1%. The expansion during the historical period is primarily due to a rise in diagnoses, an escalating number of injuries and surgeries, increased research and development, and improvements in global healthcare infrastructure.
The market size of the treatment for neurotrophic keratitis is predicted to witness substantial expansion in the forthcoming years. By 2029, it is anticipated to reach $7.39 billion with a compound annual growth rate (CAGR) of 7.6%. This growth during the forecast period is driven by educational measures, elevated numbers of clinical trials, progressive treatments, and regulatory sanctions. The forecast period is also expected to see key trends such as enhanced diagnostic instruments, solutions in digital health, strategies for neuroprotection, and advanced imaging of the ocular surface.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12968&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Neurotrophic Keratitis Treatment Market?
The escalating incidence of ailments impacting the eyes is projected to spur the expansion of the neurotrophic keratitis treatment market. Eye diseases encompass a broad array of health issues that disrupt the form and operation of the eyes. Neurotrophic keratitis therapy can assist in the enhancement of corneal sensation, catalyzing healing, averting infection, and providing relief from pain. As an illustration, in March 2022, Eye Care One, a platform dedicated to eyecare career development in the US, released reports suggesting that around 35 million American citizens will be affected by dry eye disease (DED) in 2022, with the number predicted to climb annually. Likewise, in May 2024, the Centers for Disease Control and Prevention, a federal agency operating under the US Department of Health and Human Services, disclosed that over 3.4 million Americans aged 40 and above are blind or have visual impairment, a figure slated to double by 2030. Hence, the rising prevalence of eye diseases is stimulating the growth of the neurotrophic keratitis treatment market. The surge in investments in the healthcare sector, comprising eye care, is expected to give momentum to the development of the neurotrophic keratitis treatment market. These investments denote fiscal contributions directed towards endorsing the growth, enhancement, and reach of healthcare services and remedies, with an emphasis on vision care. Such financial inputs could significantly contribute towards progress in the treatment of neurotrophic keratitis by paving the way for therapeutic breakthroughs and advancements in the creation of drugs, thereby enriching the health outcomes and quality of life of patients suffering from this condition. Providing a case in point, the Department of Health and Aged Care, an Australian government agency overseeing health research, funding, propagation, and governance, stated in March 2022 that government expenditure on health systems mounted to $132 billion in the fiscal year of 2022-23, slated to rise to $140 billion in 2025-26, with a total pledge of $537 billion over the ensuing four years. Consequently, the mounting investments in health care including eye care are fueling the expansion of the neurotrophic keratitis treatment market.
Which Key Market Segments Comprise the Neurotrophic Keratitis Treatment Market and Drive Its Revenue Growth?
The neurotrophic keratitis treatment market covered in this report is segmented –
1) By Treatment: Topical Antibiotics, Recombinant Human Nerve Growth Factor (rhNGF), Amniotic Membrane Transplantation, Keratoplasty, Other Treatments
2) By Route of Administration: Oral, Topical, Other Routes of Administration
3) By Application: Stage I, Stage II, Stage III
4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Topical Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics
2) By Recombinant Human Nerve Growth Factor (rhNGF): Cenegermin Ophthalmic Solution, Other rhNGF-Based Solutions
3) By Amniotic Membrane Transplantation: Cryopreserved Amniotic Membrane, Dehydrated Amniotic Membrane
4) By Keratoplasty: Penetrating Keratoplasty, Lamellar Keratoplasty
5) By Other Treatments: Tarsorrhaphy, Therapeutic Contact Lenses
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=12968&type=smp
Which Areas Are Leading Regions in the Neurotrophic Keratitis Treatment Market Expansion Across the Globe?
North America was the largest region in the neurotrophic keratitis treatment market in 2024. The regions covered in neurotrophic keratitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Are the Strategic Trends Steering theNeurotrophic Keratitis Treatment Market Direction?
Leading firms in the neurotrophic keratitis treatment market are pushing boundaries through the creation and approval of innovative medicines in an effort to maintain their industry standing. The field of neurotrophic keratitis treatment greatly relies on drug advancement due to the scarcity of current treatments, which further emphasizes the need for more potent treatments to halt disease progression. Case in point, in December 2022, Taiwanese clinical-stage company, BRIM Biotechnology Inc., was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for their product, BRM424, intended for neurotrophic keratitis (NK) therapy. BRM424 is a recombinant form of a human nerve growth factor designed to stimulate the growth and differentiation of corneal limbal stem cells, a crucial process in the regeneration and restoration of a patient’s cornea health suffering from neurotrophic keratitis.
View the full report here:
How Is the Neurotrophic Keratitis Treatment Market Conceptually Defined?
Neurotrophic keratitis treatment refers to a treatment method to cure a rare eye condition caused by damage to the trigeminal nerve, leading to decreased corneal sensation and potential corneal damage. This treatment is used to protect the cornea, promote healing, alleviate symptoms, and prevent further damage.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12968
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
